Younger Patients With Type 1 Diabetes: Can We Optimize Their Insulin Therapy?

Introduction/Background

Unmet Needs in Pediatric Type 1 Diabetes

PPG, HbA1c, and Risk Factor Exacerbation

Hypoglycemia and the Pediatric T1DM Patients

Recommended Targets for PPG: Association Guidelines

Post-Meal Dosing of Prandial Insulin Associated With Poorer Glycemic Control

Pharmacokinetic Action Profiles of Insulin Replacement Therapy

Faster-Acting Insulin: Approaching a More Exact Physiological Insulin Profile

Designing an Ultra-Fast Acting Insulin

994-P/994 -- Ultra-Rapid BioChaperone Lispro (BCLIS) vs Insulin Lispro (LIS): Blood Glucose and PK Parameters

Faster Onset of Appearance and Greater Early Exposure With Faster Acting Insulin Aspart vs Insulin Aspart

Onset® 1: Postprandial Plasma Glucose (Test Meal)

Onset® 1: Severe and Confirmed Hypoglycemia

Onset® 4: Incidence of Hyperglycemia

Onset® 5: PPG Increment Results After a Standardized Meal Test

Onset®7: Trial Design

Onset®7: Mean HbA1c Over Time: Mealtime and Postmeal Comparisons

Onset®7: Change in HbA1c From Baseline Was Independent of Age

Onset®7: Mean 1-Hour PPG at Week 26: Based on 8-Point SMBG Profiles

Onset®7: Treatment-Emergent Hypoglycemia After 26 Weeks

Conclusions: Onset®7

Summary and Conclusions

Abbreviations

Abbreviations (cont)